Recurv

Recurv is a U.S.-based biotechnology company dedicated to developing RP-001, a novel taxane-class anticancer compound for the treatment of solid tumors, and advancing it through clinical proof-of-concept. The project is fully funded by TVM Life Science Innovation II. In various preclinical oncology models, the asset has demonstrated robust efficacy data, potential superior safety compared to currently available taxanes, and synergy with immune checkpoint inhibitors.